Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial

G. Curigliano; J. O’Shaughnessy; F.-C. Bidard; M.L. Casalnuovo; S.-B. Kim; E. Tokunaga; P. Aftimos; C. Saura; L.A. Carey; M. Okera; E. Melo; F. Zagouri; M. Magallanes-Maciel; N. Karadurmus; S. Bahadur; RM Speck; X.A. Wang; K. Pradhan; J. Macey; H. Kitchen; S. Fairhurst; J. Miller; K.L. Jhaveri; N. Harbeck

doi:10.1016/j.esmoop.2026.106945

Key Points

To assess patient-reported outcomes and quality of life in patients with advanced breast cancer receiving treatments in the EMBER-3 trial.
Conducted a phase III trial comparing treatment arms
Included qualitative interviews and patient-reported outcomes
Evaluated quality of life metrics across treatment groups
Patient-reported outcomes and quality of life were maintained across treatment arms
Higher incidence of diarrhea was noted in the imlunestrant-abemaciclib group
Findings support a favorable risk-benefit profile for imlunestrant therapy

Implication

Phase III trial uncovers quality of life and safety in advanced breast cancer, suggesting benefits of imlunestrant therapy.

Abstract

GHS/QoL and function were maintained across treatment arms, despite a higher incidence of diarrhea in the imlunestrant-abemaciclib group. These PRO findings complement the efficacy and safety results from EMBER-3 and further support the favorable risk-benefit profile of imlunestrant, either as oral monotherapy or in combination with abemaciclib, in patients with advanced breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Curigliano et al. (2026) studied this question.

synapsesocial.com/papers/69dc874a3afacbeac03e9c7c https://doi.org/10.1016/j.esmoop.2026.106945

View Full Paper

Ask AI

Bookmark

Share

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading